XVIVO Perfusion AB earlier this month, Professor David Kaye of The Alfred in Melbourne, Australia, presented late breaking science at the American Heart Association (AHA) 2022 meeting in Chicago from an ongoing study of extended transport time of donor hearts. The impressive results showed that in the first 20 study patients transplanted with donor hearts perfused with the XVIVO heart technology there was no mortality despite very extended transport times, up to 8 hours and 47 minutes. XVIVO's technology for non-ischemic heart technology consists of a heart preservation device, a disposable set and a proprietary solution.

The Australian and New Zealand Investigator-Initiated Multicenter trial of Extended (6-8 hours) Non-Ischemic Heart Preservation (NIHP) of Donor Hearts for Transplantation is running across 5 sites and is expected to include the last patient at end of 2022. Professors David Kaye and David McGiffin of The Alfred are Principal Investigators.